Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
TDXd Better Than Chemo for HER2-Low Breast Cancer?
BARCELONA, Spain — Trastuzumab deruxtecan (TDXd) shows promise as a treatment for HER2-low and HER2-ultralow hormone receptor (HR)–positive metastatic breast cancer, according to data from the DESTINY-Breast06 trial presented here at the European Society for Medical Oncology (ESMO) Annual Meeting…
English